Novo Holdings portfolio company Hemab Therapeutics completes successful Nasdaq IPO

Portfolio company Hemab Therapeutics (COAG) has completed a successful IPO on Nasdaq, raising $346.7 million on 1 May 2026, in one of the most significant biotech listings of 2026 to date.

The Nasdaq stock offering came a little over five years after Novo Holdings initially backed Hemab to develop next-generation therapeutics for serious underserved bleeding and thrombosis disorders, marking a collaboration which began at seed stage and now has continued through the business’ IPO.

Funds raised in the offering will enable Hemab to progress its pipeline of prophylactic treatments for rare blood clotting disorders, including Glanzmann thrombasthenia (GT), Factor VII syndrome and von Willebrand disease (VWD), through clinical trials and on to commercialisation.

The oversubscribed raise is one of the largest biotech IPOs of 2026 to date. On its first day of trading, Hemab's stock closed up nearly 90% from the IPO price.

Novo Holdings has been heavily involved in Hemab’s development from early days, backing the company with seed funding as sole investor, since engaging in active ownership helping recruit at board level, and continuing to be a significant investor throughout Series A, B, and C rounds in strong investment syndicates.

Key appointments included Benny Sorensen as CEO and John Maraganore as Board Chair, as well as CFO, Mads Behrndt.

Hemab has established bases on both sides of the Atlantic, in Copenhagen and in Massachusetts, to strategically and successfully pursue the US market.

Hemab’s lead asset sutacimig (formerly HMB-001) is a subcutaneously administered bispecific antibody being developed as a first-in-class prophylactic treatment for GT.

In March 2026, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for sutacimig for the prevention of bleeding episodes in patients with GT, following a successful Phase I/II tril.

Jørgen Søberg Petersen, Senior Partner, Novo Holdings, said: “When Novo Holdings first backed Hemab at seed stage, coagulation was a field that had seen remarkably little innovation for decades. From day one, we shared management’s vision of creating a company developing prophylactic therapies for largely ignored bleeding disorders that allowed people to have a better quality of life.

By clearly positioning Hemab as a company focusing exclusively on this underserved therapeutic area, ensuring the correct strategy was put in place right at the start, and assembling both a world-class board and investment syndicate, who worked cohesively together, we have been able to meet our objectives. Being part of the journey, all the way from seed stage to IPO, has been deeply gratifying.”

Benny Sorensen, Chief Executive Officer of Hemab, said: “Having Novo Holdings as an investor, and Jørgen Søberg Petersen as a Board member has been an important part of Hemab's success to date.

Jørgen and Novo Holdings have been actively engaged at Board level throughout our journey, including in the discussions that shaped our decision to focus sutacimig on Glanzmann thrombasthenia and in the early thinking that has evolved into what is today HMB-002, a potential subcutaneous therapy for von Willebrand disease.

Jørgen Søberg Petersen has been a valued partner across all our financings, and having Novo Holdings as a lead investor has been a real strength as we completed our Series A, B, and C rounds.”